Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Repinotan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 12/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Repinotan SCHEMBL29376954 | 1.00 | HTR1A (1.00) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL1822211 | 1.00 | HTR1A (1.00) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL29711567 | 0.99 | HTR1A (0.98) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL6325494 | 0.99 | HTR1A (0.98) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL6333948 | 0.99 | HTR1A (0.98) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL1649375 | 0.98 | HTR1A (0.96) | HTR1AACHEHTR1DCA12CA9 | |
| SCHEMBL7837327 | 0.90 | HTR1A (0.81) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL7841791 | 0.89 | HTR1A (0.80) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6326346 | 0.89 | HTR1A (0.79) | HTR1AACHE | |
| SCHEMBL8971004 | 0.86 | HTR1A (0.75) | HTR1AACHECA12CA9ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775704-B1 | Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman | BAYER AG (DE) | 2001-06-06 | — | — | EP | claimed |
| JP-9143180-A | — | — | None | — | — | JP | disclosed |
| EP-4384172-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-12012380-B1 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | KULEON LLC (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240190819-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | KULEON LLC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-118055766-A | Magic and non-magic serotonin receptor agonist and its preparing process and usage | 库莱恩有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240124397-A1 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | Kuleon, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024077203-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | disclosed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| US-20030060493-A1 | Repinotan kit | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002060423-A2 | SUBSTITUTED CARBOSTYRIL DERIVATIVES AS 5-HT1A RECEPTOR SUBTYPE AGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | WO | disclosed |
| CN-1086703-C | Crystalline hydrochloride of (R)-(-)2{N-4[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | BAYER AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| EP-0775704-B1 | Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman | BAYER AG (DE) | 2001-06-06 | — | — | EP | disclosed |
| EP-0775704-B1 | Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman | BAYER AG (DE) | 2001-06-06 | — | — | EP | disclosed |
| CN-1152574-A | Crystalline hydrochloride of (R)-(-)2{N-4[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | BAYER AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| JP-H09143180-A | (R)-(-)-2-(N-(4-(1,1-DIOXIDO-3-OXO-2,3-DIHYDROBENZISOTHIAZOL-2-YL)-BUTYL)-AMINOMETHYL)-CHROMAN CRYSTAL HYDROCHLORIDE | BAYER AG | 1997-06-03 | — | — | JP | disclosed |
| EP-0775704-A1 | Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman | BAYER AG (DE) | 1997-05-28 | — | — | EP | disclosed |
| EP-0775704-A1 | Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman | BAYER AG (DE) | 1997-05-28 | — | — | EP | disclosed |
| EP-0775704-A1 | Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman | BAYER AG (DE) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060493-A1 | Repinotan kit | KIT, REN, PROKR1 | HTR1A 180/4885ACHE 783/4885HTR1D 363/4885 |
| US-20240190819-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | HTR2A, HTR2C, HTR1A | HTR1A 3/4885ACHE 642/4885HTR1D 13/4885 |
| US-20240124397-A1 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR3B | HTR1A 5/4885ACHE 1434/4885HTR1D 12/4885 |
| US-12012380-B1 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | HTR1A 3/4885ACHE 642/4885HTR1D 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.